rotation.to
Following this device: dark.
Free account
rotation.to
Appearance
Following this device: dark.
Drag a card by its title · ⚙ to size, swap or remove

The company

Trevi Therapeutics, Inc.

TRVI · Nasdaq

Health CareBiotechnologyNot moving yet

TRVI stood above a rising 150-day average in 47 of the last 52 weekly readings, and has been out of that trend for the last 5 weeks. It is 16.6% below that average now. Biotechnology: 18% of its 561 stocks in an uptrend (−12 points in four weeks); Health Care: 28% (−6 points in four weeks).

Statistics

Rotation
Not moving yet
Weeks in an uptrend
out for 5
Industry in uptrend
18% -12 in 4 wk
Insider buys, 12 months
$0
Insider sales, 12 months
$1.2M
Officials’ trades on record
0
Institutions holding
211 (+19)

In the rotation

Each square a week: lit when it closed above a rising 150-day average. 47 of 52 weeks.

22 Apr – 21 Oct
16%27%39%Apr 26Jun 26Jul 26Sep 26Oct 26

Biotechnology: Few of its stocks are in an uptrend and the share has fallen sharply over four weeks. Health Care: A minority of its stocks are in an uptrend and the share has been slipping.

Money in and out

1 Nov 2024 – 1 Oct 2026
−$1.1M$0Nov 24May 25Nov 25Apr 26Oct 26

Open-market buys above the line and sales below, in dollars.

Congress and officials

No member of Congress or official has disclosed a trade in it.

Insiders

Buy orders, 12 months0
Sale orders, 12 months1
Buyers · sellers0 · 1
WhoDidSharesTraded
Michael Thomas HeffernanDirectorsold18,321at $15.0915 Sep 2026filed 17 Sep 2026
Michael Thomas HeffernanDirectorsold100at $15.8815 Sep 2026filed 17 Sep 2026
Michael Thomas HeffernanDirectorsold20,952at $15.0915 Sep 2026filed 17 Sep 2026
Michael Thomas HeffernanDirectorsold100at $15.8815 Sep 2026filed 17 Sep 2026

Lines filed since 2 January 2026, newest first; every insider’s older lines are on their own page.

Institutions

Holders211+19 on the quarter
New · exited42 · 22
Reported value$2.8B

Quarter to 30 Jun 2026, against 31 Mar 2026; newest filing 31 Aug 2026.

ManagerSharesChange
NEA Management Company, LLCunchanged · filed 14 Aug 202613,222,228$246.6M00.0%
FMR LLCadded · filed 13 Aug 202612,562,839$234.3M+4,524,778+56.3%
BlackRock, Inc.added · filed 7 Aug 202611,155,026$208.0M+914,840+8.9%
Frazier Life Sciences Management, L.P.reduced · filed 14 Aug 20269,939,447$185.4M-1000.0%
WELLINGTON MANAGEMENT GROUP LLPadded · filed 14 Aug 20265,684,592$106.0M+495,504+9.5%
VANGUARD CAPITAL MANAGEMENT LLCadded · filed 13 Aug 20265,530,675$103.1M+552,108+11.1%
Vivo Capital, LLCunchanged · filed 14 Aug 20265,094,668$95.0M00.0%
Woodline Partners LPadded · filed 14 Aug 20264,081,333$76.1M+3,080,551+307.8%
Vestal Point Capital, LPadded · filed 14 Aug 20263,100,000$57.8M+933,496+43.1%
MPM BIOIMPACT LLCreduced · filed 14 Aug 20263,073,577$57.3M-224,853−6.8%
31 Mar 2023 – 30 Jun 2026
39122205Mar 23Dec 23Dec 24Sep 25Jun 26

News

No headline names it lately.

Everyone who traded it

Michael Thomas Heffernan Company insiderDirector · last 15 Sep 20261 · 1
Anne Vanlent Company insiderDirector · last 3 Jun 20261 · 0
David P. Meeker Company insiderDirector · last 3 Jun 20261 · 1
Dominick Colangelo Company insiderDirector · last 3 Jun 20260 · 0
Edward T. Mathers Company insiderDirector · last 3 Jun 20260 · 0
Christopher Galletta Company insiderOfficer · last 19 Feb 20260 · 0
Farrell Simon Company insiderChief Commercial Officer · last 19 Feb 20260 · 1
James Cassella V Company insiderChief Development Officer · last 19 Feb 20260 · 0
Jennifer L. Good Company insiderPresident & CEO · last 19 Feb 20261 · 8
Thomas Sciascia Company insiderChief Scientific Officer · last 19 Feb 20260 · 6
David C. Hastings Company insiderChief Financial Officer · last 8 Jan 20260 · 0
Lisa Delfini Company insiderChief Financial Officer · last 31 May 20250 · 10

Same industry

MRNA ModernaLeading+168%
ENTX Entera BioLeading+53%
XNCR XencorLeading+41%

Distance from each stock’s own 150-day average.

Government contracts

No federal award is tied to it.

From its SEC filings

Return on capital employedFY 2025 · to 31 Dec 2025-26.9%
Share count trendFY 2025 · to 12 Mar 20260.1%
Cash and equivalentsFY 2025 · to 31 Dec 2025$18.9M
Free cash flowFY 2025 · to 31 Dec 2025−$42.1M

Analyst forecasts

No analyst forecasts yet.